Eesti - eesti - Ravimiamet

tad pharma gmbh - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 14tk; 850mg+50mg 200tk

Eesti - eesti - Ravimiamet

medochemie limited - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 1000mg+50mg 168tk; 1000mg+50mg 56tk; 1000mg+50mg 180tk; 1000mg+50mg 196tk; 1000mg+50mg 30tk; 1000mg+50mg 112tk

Eesti - eesti - Ravimiamet

medochemie limited - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 180tk; 850mg+50mg 28tk; 0+50mg 14tk; 850mg+50mg 112tk; 850mg+50mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , kolmekordne kombineeritud ravi) lisandina toitumise ja treeningu patsientidel, ebapiisavalt kontrollitud nende maksimaalne talutav annus metformiin ja sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.